The relevance of BRMS1 in cancer was reinforced by the identification that BRMS1 downregulation was correlated with poor patient survival in breast cancer, ovarian cancer, melanoma, NSCLC, and nasopharyngeal carcinoma [6], [7], [9], [11], [12]. This evidence concerns the gene BRMS1 and ovarian cancer.